Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

5.290 -0.380 (-6.70%)
Delayed Quote Updated: 12:04 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kyverna Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook. 
Via The Motley Fool
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP. 
Via Benzinga
News headline image
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity ↗
Today, Dec. 15, 2025, stocks dipped as growth shares faltered and traders assessed trade risk alongside Fed commentary. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Which stocks are moving on Monday? ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Monday's session: top gainers and losers ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Which stocks are gapping on Monday? ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? ↗
In the KYSA-8 trial, a single infusion of miv-cel delivered sustained improvements across both primary and secondary measures of Stiff Person Syndrome. 
Via Stocktwits
News headline image
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline. 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026 ↗
William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy in autoimmune disease. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? ↗
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027. 
Via Benzinga
News headline image
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Top movers in Monday's after hours session ↗
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
News headline image
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q2 2024 ↗
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges ↗
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
News headline image
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.